Hot Growth Special Report 2006 >



Ventiv Health (VTIV)

If pill makers need good medicine too, then Ventiv Health is just what the doctor ordered. Based in Somerset, N.J., Ventiv Health provides clinical, communications, and commercial services to the pharmaceutical and biotech industries. A flexible, competitively priced outsourcer for Big Pharma , inVentiv positions itself as a one-stop shop for small- and mid-sized businesses by cross-servicing the entire life cycle of a drug. In 2005, the company reported consolidated sales of $556.3 million--an increase of 58% over 2004. Now it's pouring that cash back into the company, positioning it to be a leader in pharma services. Ventiv made eight acquisitions last year, including InChord Communications, previously the world's largest independent healthcare marketing company. The investment could be a spoonful of sugar to an already healthy company.

Company Info

2005 Rank


Market Value*
($ Millions)


($ Millions)


Sales Growth
(3-yr. avg. annual)

39.1 %

($ Millions)


Profit Growth
(3-yr. avg. annual)

114.0 %

Return on Inv. Capital (3-yr.)

10.9 %

Share Price
12-Mo. Hi/Lo


Share Price
As of 4/28/06


Return on Equity

17.4 %

P/E Ratio


No. of Employees


Industry Health Care Services


Location Somerset, N.J.
Phone 800 416-0555
*Trailing 12 months
Stock price data as of 4/28/06
DATA: Standard & Poor's Compustat

Related Articles

A Better Prognosis for Big Pharma

Medical Guesswork

Medicine’s Industrial Revolution

The Future of Outsourcing

Company Snapshot

Ventiv Health provides commercialization services to the pharmaceutical and life sciences industries in the U.S. and internationally. It operates through three segments: inVentiv Clinical, inVentiv Communications, and inVentiv Commercial. The inVentiv Clinical segment engages in clinical staffing and recruiting of SAS programmers, data managers, statisticians, monitors and clinical research associates, study and project managers, clinical trials coordinators, safety/regulatory staff, medical writers, scientific and laboratory staff, and other clinical personnel for pharmaceutical and biotechnology clients. This segment also provides data management and statistical analysis services, and executive placement services. The inVentiv Communications segment provides various advertising, communications, patient adherence programs, and other functionally-related services. It also provides medical education, branding consultation, interactive communication development, and consulting and contract marketing services. The inVentiv Commercial segment provides outsourced product commercialization programs for prescription pharmaceutical and other life sciences products; develops and implements data analysis and research technologies to support client decision making within pharmaceutical and biotechnology companies; provides recruitment, training and professional development, marketing support, sample management, and patient services; and licenses software solutions for the implementation of PDMA compliance strategies. The company was founded in 1997. It announced a name change to inVentiv Health in March, 2006 that should be completed by June. Ventiv Health is headquartered in Westerville, Ohio.

Data provided by Capital IQ
Eran Broshy

Eran Broshy, 47

Chief Executive Officer and Director

Total Compensation*

$ 1,138,637

Total Options Value*

$ 14,865,520

* Fiscal Year 2005

Massachusetts Institute of Technology - BS, Stanford University - MS, Harvard Business School - MBA

Executive Bio

Eran Broshy has been the CEO of inVentiv Health since its separation from Snyder Communications in September, 1999. Previously, Broshy was vice-president and health-care practice leader at the Boston Consulting Group. During his 14-year tenure at BCG, Broshy consulted widely with senior executives from a number of major global pharmaceutical manufacturers, managed-care organizations, and academic medical centers, providing solutions on a range of strategic, organizational, and operational issues. From 1998 to 1999, Broshy served as president and CEO of Coelacanth, a privately held biotechnology company. He has been a director of Ventiv Health since September, 1999. He has been a director of Neurogen since July, 2003, and is a member of its audit committee. Broshy holds a BS and an MS in civil engineering from the Massachusetts Institute of Technology and Stanford University, respectively. He also holds an MBA from Harvard Business School and is a frequent conference speaker and writer on strategic health-care issues.

Management Team

Key Executives

Eran Broshy; John R. Emery; Terrell G. Herring; Michael Hlinak; R. Blane Walter

Board Directors

Daniel Snyder; Eran Broshy; A. Clayton Perfall; Donald R. Conklin; John R. Harris; Terrell G. Herring; Per G.H. Lofberg; Mark E. Jennings; R. Blane Walter

Executive Data provided by Capital IQ